|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Progestin-androgen combination regimens for male contraception. |
| Meriggiola MC; Bremner WJ |
| JOURNAL OF ANDROLOGY. 1997 May-Jun;18(3):240-4. |
| Testosterone enanthate (TE) administration is associated with a failure rate (3.4/100 person-years) considerably |
| lower than that of other currently available reversible male contraceptive methods. However, acceptability of this |
| regimen is limited by the need for weekly injections, the lack of complete azoospermia, and the decrease in high- |
| density lipoprotein (HDL)-cholesterol. Under investigation is the concurrent administration of a progestin that can act |
| synergistically with TE in the suppression of gonadotropins. Because of the additive effects, the dose of each |
| steroid can be decreased, minimizing androgen-related side effects. Third-generation progestins and hybrid |
| progestins seem to offer the most potential for such an approach. In particular, the combination of cyproterone |
| acetate (CPA) and TE has been found to result in a rapid, profound suppression of spermatogenesis, without side |
| effects, through its ability to block both the follicle-stimulating hormone and androgen effects at the testis level. The |
| anti-androgenic action of CPA is based on its ability to competitively inhibit the binding of testosterone and |
| dehydrotestosterone to androgen receptors. The block of intratesticular testosterone effect by CPA is presumed to |
| cause a decrease in cell-adhesion molecule concentrations and contribute to the premature sloughing of permatids |
| from the seminiferous epithelium, thereby resulting in the early disappearance of spermatozoa from the ejaculate. |
| This regimen did not cause any changes in plasma HDL or other lipoproteins or affect liver function test results. |
| (PubHealth.info Document ID: CONT2T 1009-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Progestin-androgen combination regimens for male |
| contraception.", is(are) Meriggiola MC; Bremner WJ. The source of this article is "JOURNAL OF ANDROLOGY. 1997 |
| May-Jun;18(3):240-4.". This article was published in 1997 in English language(s). (PubHealth.info® Document ID: |
| CONT2T 1009-06. All rights reserved with PubHealth.info) PIN: 6009 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
